MIAMI, Fla. — September 14, 2026
Telomir Pharmaceuticals, Inc. announced new research conducted with The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn inhibited cell growth across human and canine osteosarcoma models. The preclinical study evaluated the compound in three osteosarcoma cell lines, including HOS human cells and D17 and Abrams canine cells, with all three models showing growth inhibition at similar low drug concentrations. The findings provide an initial translational foundation for evaluating Telomir-Zn in naturally occurring canine osteosarcoma while the company continues advancing its primary triple-negative breast cancer (TNBC) program toward clinical site initiation and Phase 1/2 enrollment. Telomir said the cross-species activity supports exploration of osteosarcoma as a potential additional development pathway for its oncology platform.
Canine Osteosarcoma Provides Translational Development Opportunity
The Ohio State research highlights the potential value of naturally occurring canine osteosarcoma as a translational model for human cancer development. Osteosarcoma is the most common primary bone malignancy in children and young adults, while the disease also represents a major oncology challenge in large-breed dogs. Metastatic human osteosarcoma continues to have poor outcomes despite decades of chemotherapy-based treatment, with survival rates remaining below 30% according to the company. Telomir noted that canine and human osteosarcoma share similarities in genetics, tumor biology and therapeutic response patterns, making canine disease potentially useful for evaluating new therapies in a naturally occurring setting. Based on the observed in-vitro activity, Telomir is discussing potential next steps with Ohio State, including an in-vivo efficacy study in canine osteosarcoma. Such research could generate additional evidence for veterinary development while potentially informing future human osteosarcoma studies.
Telomir-Zn Uses Iron-Modulation Mechanism
Telomir-Zn is designed to target intracellular iron and copper homeostasis and influence cancer-associated epigenetic pathways. According to Telomir, the compound disrupts intracellular labile iron pools and inhibits iron-dependent histone demethylases (KDMs), mechanisms intended to reverse cancer-associated epigenetic silencing. The osteosarcoma experiments provide an early opportunity to examine whether this mechanism can produce anti-tumor activity across both human and canine cellular models. However, the current findings are limited to preclinical in-vitro studies and do not establish clinical efficacy in either species. The company is therefore evaluating additional translational work to determine whether the observed growth inhibition can be reproduced in more advanced disease models. This approach could also help establish a development bridge between veterinary oncology research and potential future human applications.
Advertisement
Telomir Maintains TNBC-Led Clinical Strategy
While osteosarcoma represents a potential expansion opportunity, Telomir’s immediate clinical priority remains its TNBC program. The company has an active FDA-cleared IND supporting a planned Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer, with site initiation and patient enrollment now being prepared. Telomir is evaluating the osteosarcoma program as a parallel pathway, potentially beginning with additional canine studies before determining whether broader development is warranted. This creates a two-track strategy in which the lead TNBC program advances toward human clinical testing while veterinary osteosarcoma research could provide an additional setting for translational validation of Telomir-Zn. If supported by further in-vivo and clinical evidence, the parallel development model could expand the potential indication profile of Telomir-Zn while strengthening the company’s broader strategy around small-molecule therapies targeting epigenetic and metabolic drivers of cancer.
Source:Telomir Pharmaceuticals, press release
